Immunotherapy doubles overall survival
and improves quality of life, with fewer side effects, in a treatment - resistant
and rapidly
progressing form of
head and neck carcinoma, reports a large, randomized international trial co-led by investigators at the University of Pittsburgh
Cancer Institute (UPCI).
At the ONJ Centre clinical trials are in
progress for a variety of
cancer types including brain, bowel, breast, melanoma, gastrointestinal,
head and neck, pancreatic, prostate
and lung
cancer.